Testing mirdametinib and vorinostat for NF1-related MPNST
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You must have a diagnosis of neurofibromatosis type 1 (NF1).
- You must have a tumor that is suspected to be a malignant peripheral nerve sheath tumor (MPNST).
- The tumor must test negative for a specific protein marker (H3K27 trimethylation).
- You must be able to swallow capsules.
- If you are of childbearing age, you must agree to use effective birth control during and for a few months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This trial tests two oral targeted drugs, avutometinib and defactinib, for malignant peripheral nerve sheath tumor (MPNST) that has come back or spread. The hope is that these drugs can shrink or slow the tumor where chemotherapy hasn't worked.
This trial tests a study drug called mirdametinib in infants and toddlers who have neurofibromatosis type 1 (NF1) with plexiform neurofibromas (non-cancerous nerve tumors). The study aims to see if the drug can shrink or control these tumors, which may help prevent or reduce symptoms.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This trial tests a drug called mirdametinib, which targets a protein linked to tumor growth, given alone or with radiation. It is for people with certain brain or spinal cord tumors, especially those with a condition called NF1, to see if it can help control the cancer.
This trial tests an experimental oral drug called mirdametinib for people with advanced melanoma that has a specific gene change (NF1 mutation). To join, you must have already had immunotherapy, but not a MEK/ERK/RAF targeted drug before.
Hear when a new Primary Malignant Peripheral Nerve Sheath Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.